Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EBITDA (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed EBITDA for 7 consecutive years, with -$139.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 38.25% to -$139.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$523.4 million through Dec 2025, up 11.73% year-over-year, with the annual reading at -$523.4 million for FY2025, 11.73% up from the prior year.
  • EBITDA hit -$139.6 million in Q4 2025 for BridgeBio Pharma, up from -$145.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $343000.0 in Q1 2024 to a low of -$226.0 million in Q4 2024.
  • Historically, EBITDA has averaged -$140.6 million across 5 years, with a median of -$145.6 million in 2023.
  • Biggest five-year swings in EBITDA: skyrocketed 100.27% in 2024 and later crashed 30529.15% in 2025.
  • Year by year, EBITDA stood at -$165.6 million in 2021, then grew by 21.97% to -$129.2 million in 2022, then tumbled by 37.28% to -$177.4 million in 2023, then dropped by 27.4% to -$226.0 million in 2024, then skyrocketed by 38.25% to -$139.6 million in 2025.
  • Business Quant data shows EBITDA for BBIO at -$139.6 million in Q4 2025, -$145.2 million in Q3 2025, and -$134.3 million in Q2 2025.